Vinflunine is the only cytotoxic agent tested as a second line therapy in transitional cell carcinoma of the urothelium in a phase III trial. It is not largely employed in clinical practice because of the high incidence of grade 3-4 toxicity. We evaluated efficacy and safety of Vinflunine at the dose of 280 mg/m2 every 3 weeks associated with primary prophylaxis with granulocyte growth factors and laxatives for patients progressed after platinum + Gemcitabine. Overall survival was 8.5 months, progression-free survival 4.33 months and response rate 25%, with disease control rate 57.2%. Grade III-IV neutropenia occurred in 10.7% of the patients, grade III-IV anemia and grade III thrombocytopenia in 10.7% and 7.2%, respectively. Among non haematological toxicity, grade I-II constipation was reported in 14.2% of the patients, without grade III-IV adverse events. No discontinuation for toxicity was observed. This study underlines that Vinfluinine at a dose of 280 mg/m2associated with primary prophylaxis for neutropenia and constipation is effective and with a favorable toxicity profile.

Schinzari, G., Rossi, E., Pierconti, F., Garufi, G., Monterisi, S., Strippoli, A., D'argento, E., Cassano, A., Barone, C., Monoinstitutional real world experience in management of vinflunine as second line therapy for transitional cell carcinoma of the urothelium, <<ONCOTARGET>>, 2018; 9 (9): 8765-8771. [doi:10.18632/oncotarget.24162] [http://hdl.handle.net/10807/122904]

Monoinstitutional real world experience in management of vinflunine as second line therapy for transitional cell carcinoma of the urothelium

Schinzari, Giovanni;Rossi, Ernesto;Pierconti, Francesco;Garufi, Giovanna;Monterisi, Santa;Strippoli, Antonia;D'Argento, Ettore;Cassano, Alessandra;Barone, Carlo
2018

Abstract

Vinflunine is the only cytotoxic agent tested as a second line therapy in transitional cell carcinoma of the urothelium in a phase III trial. It is not largely employed in clinical practice because of the high incidence of grade 3-4 toxicity. We evaluated efficacy and safety of Vinflunine at the dose of 280 mg/m2 every 3 weeks associated with primary prophylaxis with granulocyte growth factors and laxatives for patients progressed after platinum + Gemcitabine. Overall survival was 8.5 months, progression-free survival 4.33 months and response rate 25%, with disease control rate 57.2%. Grade III-IV neutropenia occurred in 10.7% of the patients, grade III-IV anemia and grade III thrombocytopenia in 10.7% and 7.2%, respectively. Among non haematological toxicity, grade I-II constipation was reported in 14.2% of the patients, without grade III-IV adverse events. No discontinuation for toxicity was observed. This study underlines that Vinfluinine at a dose of 280 mg/m2associated with primary prophylaxis for neutropenia and constipation is effective and with a favorable toxicity profile.
eng
http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=download&path%5B%5D=24162&path%5B%5D=75949
Schinzari, G., Rossi, E., Pierconti, F., Garufi, G., Monterisi, S., Strippoli, A., D'argento, E., Cassano, A., Barone, C., Monoinstitutional real world experience in management of vinflunine as second line therapy for transitional cell carcinoma of the urothelium, <>, 2018; 9 (9): 8765-8771. [doi:10.18632/oncotarget.24162] [http://hdl.handle.net/10807/122904]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/122904
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? ND
social impact